SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC’s Recentin Flunks Colon Cancer Tests

May 28, 2010 | 
1 min read
LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file experimental cancer drug Recentin as a first-line treatment for colon cancer on Friday after disappointing results from a second pivotal clinical trial with the medicine.
Clinical research Phase 2
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Red round circle with a pause button or icon against yellow background.
Gene therapy
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
February 9, 2026
 · 
1 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Gene therapy
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
February 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Graphic drawing white background
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
February 6, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Immunology and inflammation
Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
February 6, 2026
 · 
2 min read
 · 
Tristan Manalac